The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Further strengthens BaseLaunch's global pharma industry partnerships
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Launch of 20 new medicines expected by 2030
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
The award recognizes powerful science–industry collaborations for social good
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Subscribe To Our Newsletter & Stay Updated
